Filing Flows › Health Care › Femasys (FEMY)
Femasys (FEMY) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · Femasys (FEMY) Q2 2026 earnings results →
Q2 2026 Revenue down 19% year over year to $332K
Femasys made $332K in Q2 2026 (-19% Y/Y). Operating margin n/m, net loss $4.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $332K in Q2 2026, down 19% year over year and down 22% from the previous quarter.
Operating costs exceeded revenue by $5.1M, an operating margin of -1526.7%. Total costs grew 27% against a revenue fall of 19%. The fastest-growing cost line was Research & development (+38%). The quarter ended with a net loss of $4.5M, after a profit of $846K the previous quarter.
Operating cash flow was −$3.9M. Non-cash charges added back $83K of depreciation and amortization and $211K of share-based compensation. Working capital and other items added $240K. Capital expenditures of $9K exceeded it, leaving free cash flow of −$3.9M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $332K | -19% | n/m | −$4.5M | −$3.9M |
| Q1 2026 | 10-Q | May 8, 2026 | $425K | +24% | -994.0% | $846K | −$4.1M |
| Q4 2025 | 10-K | Mar 31, 2026 | $813K | +40% | -568.3% | −$4.0M | −$4.2M |
| Q3 2025 | 10-Q | Nov 14, 2025 | $729K | +31% | -500.9% | −$4.2M | −$5.4M |
| Q2 2025 | 10-Q | Aug 8, 2025 | $409K | +85% | -941.1% | −$4.6M | −$4.4M |
| Q1 2025 | 10-Q | May 8, 2025 | $341K | +26% | n/m | −$5.9M | −$4.8M |
| Q4 2024 | 10-K | Mar 27, 2025 | $582K | +173% | -812.0% | −$5.1M | −$5.1M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Femasys
Femasys is a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide. The Company is focused on commercializing its fertility portfolio, led by FemaSeed ® Intratubal Insemination, together with complementary diagnostic and sperm preparation products, in the U.S. and key international markets. Femasys is also advancing FemBloc ® , its non-surgical, in-office permanent birth control solution, toward U.S. FDA approval through the ongoing FINALE pivotal trial (NCT05977751). FemBloc received regulatory approvals in Europe, the UK and New Zealand in 2025, supporting commercialization through strategic partnerships in select international markets.
In its own words, from its 8-K, filed Aug 14, 2026.
Femasys against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -19% against the peers' median +5%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| FEMY Femasys | Q2 2026 | $332K | -19% | n/m |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Femasys 10-Q on SEC EDGAR · CIK 1339005 · Surgical & Medical Instruments & Apparatus
13F: who owns FEMY and who is buying
More on FEMY
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results